Fresenius Delayed By FDA Inspection Uncertainty As It Works Towards US Pegfilgrastim Launch
Biosimilars Head Ali Ahmed Talks About Company’s Biosimilars Strategy
Executive Summary
Ali Ahmed, senior vice president of biosimilars at Fresenius Kabi, considers the launch of the firm’s proposed Neulasta (pegfilgrastim) biosimilar in the US “an important milestone for the company.” However, he explains in an exclusive interview with Generics Bulletin, delays to necessary FDA inspections are creating uncertainty for the firm over launch timing.